Lilly, Roche to get expedited FDA review for blood test to diagnose Alzheimer’s disease
Roche and Lilly said they believe the test could play an important role in improving access to early and accurate Alzheimer’s diagnosis.
Eli Lilly and Co.
-
Lilly factory in New Jersey comes under more federal scrutiny
Lilly said it was working closely with the FDA and the “situation does not affect the quality, safety or supply of any current or planned Lilly products in the marketplace.”
Read More -
Lilly’s soaring stock, Fishers’ innovation park among top 10 life sciences stories of 2023
It was a busy year for the Indiana life sciences community, with a flurry of billion-dollar deals, major announcements, and a few setbacks. Here we present the top 10 stories of 2023—the good, the bad and the ugly—about an industry that is often hailed as a key driver of Indiana’s economy.
Read More -
Lilly experimental drug lowers heart disease risk factor in just one dose, study finds
Lilly’s lepodisiran, given at the highest dose, reduced a heart disease-linked protein to undetectable levels for 48 weeks, according to the study.
Read More -
Lilly bracing for demand crush for newly approved obesity drug
The Indianapolis-based drug company is ramping up manufacturing capacity to avoid possible shortages and to meet potentially huge demand in a nation where more than 40% of adults are classified as obese.
Read More
Articles
No degree needed: Lilly hires more than 130 through Skills First program
Eli Lilly’s Skills First initiative is made up of four apprenticeship programs that prepare people for positions in manufacturing, IT, research labs, marketing, or administrative services.
Lilly jabs at people who use new weight-loss drugs ‘for vanity’
The Indianapolis-based drugmaker, which makes weight-loss drug Zepbound and diabetes drug Mounjaro, recently aired a new 30-second spot, just ahead of the Academy Awards, to underscore the message.
FDA delays Alzheimer’s drug for further review in surprise move
The call for additional scrutiny surprised Lilly executives, who noted that it is unusual for such a review to occur after the FDA has given an anticipated date to make a decision on approval. An OK for the drug had been expected this month.
New weight-loss drugs designed for long-term use, but some patients want to stop
Millions of Americans who have dropped pounds and boosted their health using popular obesity drugs like Wegovy and Eli Lilly and Co.’s Mounjaro and Zepbound are finding out what happens when they stop taking them.
Lilly employees have seen big wins as stock price surges 500% since 2019
In the past 52 weeks, shares have set new records almost every week, due to investor eagerness over the company’s new drugs for obesity and diabetes, two health conditions that plague America, along with other drugs in the pipeline.
Lilly stock surges on analyst’s ‘$1 trillion club’ comment
Shares in the Indianapolis-based drugmaker are setting new records almost every day, due to investor excitement over the company’s new drugs for obesity and diabetes, two health conditions that plague America.
As Lilly stock skyrockets, endowment gifts surge
In recent weeks, the Indianapolis-based philanthropy has been unveiling a flurry of gifts at the $100 million level or higher.
Eli Lilly, Novo Nordisk race to meet demand for weight-loss drugs
As Novo and Lilly fight to dominate the market in weight-loss drugs, gaining an edge in manufacturing power is emerging as a new front. Both drugmakers are racing to secure the highly specialized plants that can churn out enough of their top-selling drugs to keep up with demand.
Big Pharma targeting smaller companies, with megadeals now out of favor
Indianapolis-based Eli Lilly and Co. and Switzerland-based Novartis were the most active acquirers in the past 12 months, with seven and six deals respectively, according to data compiled by Bloomberg.
Lilly sees fourth-quarter profit jump 13%, with strong demand for Mounjaro and Zepbound
The Indianapolis based drugmaker posted net income of $2.19 billion for the quarter. Excluding nonrecurring items, adjusted earnings per share of $2.49 beat the FactSet consensus of $2.30.
IU, Lilly roll out co-op partnership to address Indiana’s workforce shortage
The partnership will connect undergraduate students and degree programs from the IU Indianapolis campus with opportunities at Lilly, such as finance, human resources and information technology.
Riley Children’s Foundation sets up nutrition research partnership with $2.5M gift from Lilly CEO’s foundation
In addition, the Ricks Family Foundation says it will match up to an additional $2.5 million in donations from individuals, foundations and corporations.
Lilly launches online service that offers home delivery of weight-loss, diabetes, migraine drugs
Among the medications listed as available through LillyDirect Pharmacy Services is Zepbound, the company’s popular new weight loss treatment, which is projected to exceed $2 billion in sales in 2024.
2023 Newsmaker: Ricks leads Lilly to new heights
David Ricks led Eli Lilly and Co. to milestone after milestone in 2023, with a slew of product launches for diseases from obesity to inflammatory bowel disease. And when Lilly wasn’t scoring wins in the laboratory, it was issuing a series of head-turning announcements,
2023 Year in Review: Lilly had a ‘big-deal’ year
Among other big dealmakers in 2023 was Hillenbrand Inc., Jasper-based Kimball International Inc. and Noblesville-based Helmer Scientific Inc.
Legislative push brewing to make new weight loss drugs more accessible
Obesity drugs like Wegovy and Eli Lilly’s Zepbound are showing promising results in helping people shed pounds. But a law bans Medicare from paying for weight loss drugs. Now, drugmakers and a bipartisan coalition of lawmakers are gearing up to push for that to change next year.
Point Biopharma shares sink 11% on study results; Lilly acquisition still up in air
Results of a clinical trial for Point Biopharma’s lead compound fell short of analysts’ expectations, and that development is likely to pressure its investors to decide whether to agree to sell the company to Eli Lilly and Co. for $1.4 billion.
Lilly stock slips after study finds patients who stop Zepbound regain weight
People who stopped taking Eli Lilly and Co.’s blockbuster drug Zepbound after about eight months regained half the weight they’d lost a year later, yet were significantly thinner than when they had started the obesity drug, according to a new study.
Lilly launches obesity drug, but insurers balk over price
The new drug, called Zepbound, carries a hefty price of $1,059.87 per month, and insurers and health care plans are balking, questioning its affordability. Many employers and government health programs exclude obesity treatments from their coverage.